Background and Aim: Hepatocellular carcinoma (HCC) is the third most common reason for cancer-related death worldwide. Many countries either lack appropriate clinical practice guidelines for the ...
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
"To our knowledge, our study represents the first randomized, global study to report data for an anti-TIGIT monoclonal antibody in hepatocellular carcinoma," Finn and colleagues wrote in Lancet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback